Safety of Simvastatin and Goal Attainment for Low-Density Lipoprotein Cholesterol in Sultan Qaboos University Hospital


Abstract

Objectives: Despite the scientific evidence of reducing cardiac events with HMG Co-A reductase inhibitors (statins) therapy in both primary and secondary preventions, these therapies continue to be underutilized in patients receiving convivial care. Simvastatin, a HMG Co-A inhibitor agent, is the most commonly used statin in Sultan Qaboos University Hospital. The aim of this study is to review the safety and the effectiveness of achieving LDL-C targets with Simvastatin according to the NCEP-ATP3 guidelines in patients with different cardiovascular risk categories at Sultan Qaboos University Hospital.

Methods: A retrospective chart review was conducted for 160 patients. Patients were identified by outpatient prescriptions provided by pharmacy department from April 2008 to May 2008. Results: 98% of the patients were prescribed simvastatin 20 mg and only 2% received 40 mg. The mean age of patients was 57 years +/- 12. While 49% of the patients were male and 45% had diabetes mellitus, 50% had cardiovascular disease, 2.5% were smokers, 67% were hypertensive, and 3% had positive family history of coronary artery disease. 75% of patients were classified as high risk, 7% moderate risk and 18% low risk for coronary artery disease. Among all lipid profiles, only LDL-C was changed from baseline with simvastatin treatment in all patients (3.60±1.03 to 3.25±1.34 mmol/L). LDL-C level at baseline was higher in the high risk group (4.11±1.06 mmol/L) compared to low and moderate risk groups (3.68±0.89, 3.42±1.15) respectively. Achievement of LDL-C goals was achieved in only 43% for high risk, 50% in moderate risk, and 90% in low risk patients. There was no significant increase in liver enzymes and creatinine kinase.

Conclusion: This study identified that more than half of the high risk patients were not at the target LDL-C goals which place them at a continuous risk of coronary heart disease. More appropriate lipid lowering therapy using more potent statins or combination therapy should be optimized to improve achievement of LDL-C goals according to ATP-III guidelines.

From the 1Department of Pharmacy, Qatar Heart Center, Qatar; 2Department of Internal Medicine, SQUH; 3Department of Clinical Biochemistry, SQUH; 4Department of Clinical Pharmacy, SQUH; 5Department of Internal Medicine, College of Medicine and Health Sciences, SQU; 6Department of Pharmacology and Clinical Pharmacy, College of Medicine & Health Sciences, SQU.

Received: 02 June 2010
Accepted: 04 Aug 2010

Address correspondence and reprint request to: Dr. Khalid Al-Rasadi, Department of Clinical Biochemistry, Sultan Qaboos University Hospital, Al Khod, Sultanate of Oman.
E-mail: khalid77@squ.edu.om

doi:10.5001/omj.2010.79

Introduction

Dyslipidemia is a strong risk factor for myocardial infarction, and serum cholesterol concentrations have been shown to be directly related to mortality from coronary heart disease (CHD).

Lower low-density lipoprotein cholesterol (LDL-C) blood concentrations are associated with lower cardiovascular disease risk, reduction in peripheral vascular disease, and reduction in both fatal and non-fatal vascular events as shown by the Heart Protection Study. Several randomized controlled trials enrolling a wide variety of patients confirmed that for every 1 mmol/L reduction in serum LDL-C by statin treatment, the relative risks of cardiovascular events and mortality are decreased by 21% and 12% respectively.

Several recent studies have shown that intensive LDL-C lowering of <1.8 mmol/L in patients with coronary heart disease decreased cardiovascular events significantly. In the Treating to New Targets (TNT) study, patients who received atorvastatin 80mg had 22% relative risk reduction in major cardiovascular events, fewer additional coronary artery disease (CAD)-related hospitalizations (35% vs. 41%) and revascularization procedures (16% vs. 22%) than those treated with atorvastatin 10 mg.

Post-hoc analysis of coronary artery bypass graft surgery (CABG) patients from the TNT trial showed intensive LDL-cholesterol lowering to a mean of 2.05 mmol/l with atorvastatin 80 mg/day decreased major cardiovascular events significantly by 27% and the need for repeat coronary revascularization by 30%, compared to atorvastatin 10 mg/day. Although higher doses of statins can result in more adverse side effects, a Meta analysis of 7 randomized clinical trials showed more intensive regimens compared with lower intensity regimens were associated with small absolute increases in rates of drug discontinuation (2.5%), elevated levels of aminotransferases (1%) and myopathy (0.5%), and there was no difference in non-cardiovascular mortality.

Based on these evidence, NCEP-ATP III updated guidelines recommended to decrease LDL-C to less than 2.6 mmol/l in high risk patients (patient with established coronary artery disease, CAD risk equivalents and estimated 10 years risk for myocardial infarction (MI) more then 20%). In patients with very high risk (those with established coronary artery disease and either diabetes mellitus (DM), smoking, metabolic syndrome and acute
coronary syndrome) LDL-C should decrease below 1.8 mmol/l as an optional target. European guidelines recommend a target LDL-C of <2.5 mmol/L in patients with CAD. The American and Canadian guidelines on the other hand, recommend a target LDL-C of < 2.0 mmol/L in these patients.

This study was conducted to evaluate the safety and the effectiveness of achieving LDL-C targets with Simvastatin according to the NCEP-ATP III guidelines in patients with different risk categories at Sultan Qaboos University Hospital.

Methods

This study was a retrospective chart review carried out between April 2008 and May 2008. Patients on simvastatin were identified by reviewing prescriptions provided by the outpatient pharmacy department. Patients were included if they were >18 years of age, and completed a minimum of three months simvastatin therapy. Patients were classified into mild, moderate and high risks for cardiovascular event according to NCEP-ATP-III guidelines based on the presence of one or more cardiovascular risk factors, presence of diabetes, and calculated Framingham risk score. Patients were excluded if they received combination of lipid lowering agents.

The results of lipid values (total cholesterol (TC), triglycerides (TG), LDL-C and HDL-C) were measured at SQU biochemistry laboratory. TC and TG were measured by enzymatic, colorimetric methods. HDL-C and LDL-C were measured by homogeneous enzymatic colorimetric methods. Lipid results were obtained from the laboratory information system before statin treatment and a minimum of 3 months after treatment.

Adverse events were obtained from laboratory data (measurements of ALT and CK). No clinical signs or symptoms were reviewed.

For categorical variables, frequencies and percentages were reported and for continuous variables, means and standard deviations (±SD) were presented. Mean differences between groups were analyzed using paired t-tests. An a priori two-tailed level of significance was set at the 0.05 level. Statistical analysis was performed using STATA version 9.1 software.

Results

224 prescriptions were reviewed over one week. A total of 160 patients were included (78 males and 82 females). A total of 64 patients were excluded; 44 patients of whom used simvastatin for <3 months, 14 patients were shifted from fluvastatin to simvastatin, 2 patients were <18 years and 4 patients used simvastatin with fenofibrate.

Baseline characteristics of all patients are summarized in Table 1. Mean age was 57±12 years, and mean weight 73.4±15.9 kg. 72 patients (45%) were diagnosed with cardiovascular disease and co-diagnoses with myocardial infarction and angina being the most common diagnoses. 80 patients (50%), had diagnosis of DM (2 with type 1 DM, 78 with type 2 DM), 107 (67%) had hypertension, 4(2.5%) were smokers and 5(3%) had family history of CAD.

The majority of patients were high risk patients (75%), 7% of the patients were moderate risk and 18% were low risk.

Table 1: Patient characteristics at baseline:

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Mean ± SD or No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>57±12</td>
</tr>
<tr>
<td>Weight (kg)</td>
<td>73.4±15.9</td>
</tr>
<tr>
<td>Male</td>
<td>78(49)</td>
</tr>
<tr>
<td>Female</td>
<td>82(51)</td>
</tr>
<tr>
<td>Diagnosis of Diabetes Mellitus</td>
<td></td>
</tr>
<tr>
<td>Type 1 DM</td>
<td>80(50)</td>
</tr>
<tr>
<td>Type 2 DM</td>
<td>2(1)</td>
</tr>
<tr>
<td>Cardiovascular Disease</td>
<td></td>
</tr>
<tr>
<td>Myocardial Infarction</td>
<td>72(45)</td>
</tr>
<tr>
<td>Stroke</td>
<td>2(1)</td>
</tr>
<tr>
<td>Angina</td>
<td>7(4)</td>
</tr>
<tr>
<td>Congestive Heart Disease</td>
<td>4(3)</td>
</tr>
<tr>
<td>MI+CHF</td>
<td>5(3)</td>
</tr>
<tr>
<td>Stroke+CHF</td>
<td>3(2)</td>
</tr>
<tr>
<td>MI+CHF</td>
<td>48(30)</td>
</tr>
<tr>
<td>Smoker</td>
<td></td>
</tr>
<tr>
<td>No smoker</td>
<td>4(3)</td>
</tr>
<tr>
<td>No HTN</td>
<td></td>
</tr>
<tr>
<td>Family history CHD</td>
<td>107(67)</td>
</tr>
<tr>
<td>No family history CHD</td>
<td>6(4)</td>
</tr>
<tr>
<td>Family history CHD</td>
<td>5(3)</td>
</tr>
<tr>
<td>No family history CHD</td>
<td>3(2)</td>
</tr>
</tbody>
</table>

* MI: Myocardial Infarction; CHF: Congestive Heart Failure; HTH: Hypertension; CHD: Coronary Heart Disease

Duration of treatment was >12 months in 113 (71%) and between 3-12 months in 47 (29%) of the patients. Almost all patients received simvastatin dose of 20 mg in (98%) and 40 mg dose in only 2% of the patients.

LDL-C concentration prior to simvastatin treatment (pre-index) was available for 58 (36%) patients, 79 (49%) patients for post-treatment (post-index) and for 30 (19%) pre and post index.

Table 2 summarizes the lipid profile at baseline and post treatment for the 160 patients according to their risk groups. LDL-C concentration decreased significantly for all groups after treatment (3.60±1.03 to 3.25±1.34 mmol/L). The mean LDL-C in the high risk group was 4.11±1.06 mmol/L pre-treatment and 3.38±1.28 mmol/L post-treatment.
Safety of Simvastatin and Goal... Al-Siyabi et al.

Table 2: Lipid profile pre and post simvastatin treatment.

<table>
<thead>
<tr>
<th>Type of Lipid</th>
<th>Low Risk</th>
<th>Moderate Risk</th>
<th>High Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Pre-treatment (mmol/l)</td>
<td>Post-treatment (mmol/l)</td>
<td>Pre-treatment (mmol/l)</td>
</tr>
<tr>
<td>Total Cholesterol</td>
<td>5.41±0.89</td>
<td>5.11±0.79</td>
<td>5.55±2.33</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>1.47±0.67</td>
<td>1.48±0.68</td>
<td>2.57±0.81</td>
</tr>
<tr>
<td>LDL-C</td>
<td>3.68±0.89</td>
<td>3.356±0.69</td>
<td>3.42±1.15</td>
</tr>
<tr>
<td>HDL-C</td>
<td>1.30±0.43</td>
<td>1.26±0.37</td>
<td>0.92±0.15</td>
</tr>
</tbody>
</table>

* LDL-C: Low Density-Lipoprotein Cholesterol; HDL-C: High-Density-Lipoprotein Cholesterol

LDL-C level at baseline was higher in the high risk group (4.11±1.06 mmol/L) compared to low and moderate risk groups (3.68±0.89, 3.42±1.15). In high risk patients, 22/51(43%) reached LDL-C target of <2.60 mmol/L. In the moderate risk group, 4/8(50%) reached LDL-C target of <3.40, and in the low risk group, 18/20 (90%) achieved LDL-C target of <4.10.

ALT was available for 83(52%) pre-index, 101(63%) post-index and for 49(31%) pre and post-index. Compared to baseline, ALT did not change significantly post-treatment with simvastatin (from 24±19 to 23±20). CK measurements were available in 4(2.5%) pre-index with mean 79±39 IU/L, 6(3.7%) post-index with mean 24±19 to 23±20). CK measurements were available in 4(2.5%) pre-index with mean 79±39 IU/L, 6(3.7%) post-index with mean 102±56 IU/L and no documentation for pre and post-index.

Discussion

National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATPIII) sets LDL-C as the primary target for cholesterol lowering therapy. LDL-C should be lowered to <2.60 mmol/L in patients with established CAD or CAD risk equivalents like DM and other CVs. LDL-C of ≤1.8 mmol/L is an optional target for patients with CAD with multiple major or uncontrolled risk factors like DM, smoking and obesity.

In this study, 43% of the high risk patients achieved LDL-C target of <2.6 mmol/L. Compared to other studies, data from the Lipid Treatment Assessment Project (L-TAP) study showed an overall 37% of high risk patients achieved NCEP-specified LDL-C target level. In the L-TAP study, the success rate for the high risk patients on simvastatin was 50%. This is still a low percentage for LDL-C attainment. Also, it was observed that 49% of patients had no post-index LDL-C level to be evaluated which could partly be explained by physicians not adhering to guidelines or poor patient compliance. It was also revealed that 71% of the patients were on simvastatin for >12 months and 98% were on a low starting dose of 20 mg. The doses of simvastatin were not titrated to a maximum dose to reach the LDL-C targets. The mean LDL-C at baseline for the high risk group was higher than the LDL-C levels in low and moderate risk groups. To achieve LDL-C target of <2.6 mmol/L in this group, LDL-C should be decreased at least by 40% and simvastatin at 40 mg would be an appropriate starting dose.

The updated NCEP-ATP3 guidelines specify LDL-C <1.8 mmol/L as an optional target for CHD with multiple risk factors. These recommendations indicate using even a higher dose of statin, more potent statin or combination with fibrate, niacine, bile acid sequestrant or ezetimibe, should be considered as starting therapy for these patients. In patients with multiple risk factors and at a high risk for CHD, ezetimibe added to statin was markedly superior to placebo added to statin in achievement of NCEP ATP II LDL-C treatment goals (72% vs. 19%, p<0.001).

At relative starting doses, 10 mg ezetimibe/20 mg simvastatin once daily has been shown to lower LDL-C levels more than atorvastatin at its starting doses of 10 mg or 20 mg once daily. At the highest doses, 10 mg ezetimibe/80 mg simvastatin lowers LDL-C more than atorvastatin 80 mg per day. Although conflicting data exists regarding the effect of ezetimibe when added to statin on atherosclerosis progression, still it is considered as an effective drug in lowering cholesterol.

The efficacy of colesevelam, a unique bile acid sequestrant has been evaluated in combination with statins. The administration of 6 tablets of colesevelam with statins has been shown to result in an approximate 10-16% further reduction in LDL-C levels, favorable effects upon HDL-C levels, and mild to moderate elevations in triglyceride levels. The combination of niacin with statins have complementary benefits on multiple lipoprotein parameters, especially HDL.
Trial Evaluation (ADVOCATE), the combination of niacin ER plus lovastatin was more effective than either atorvastatin or simvastatin alone in increasing LDL peak particle diameter and was more effective than either atorvastatin or simvastatin alone in increasing the proportion of HDL in "cardio protective" 2b subclass. Additionally, the combination of niacin and simvastatin lowered LDL-C levels by 42%, increased HDL-C by 26% and reduced CHD events by 60-90%. During the period of this study, simvastatin and fenofibrate were the only medications available at SQUH. In the Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (SAFARI) trial, combination therapy of fenofibrate 160 mg and simvastatin 20 mg resulted in additional decreased TG by 43%, increased HDL-C by 18.6% and decreased LDL-C by 31.2% compared to simvastatin 20 mg monotherapy. Higher rate of drug-related adverse events were also observed. Only patients on simvastatin monotherapy were evaluated and patients on combination therapy were excluded in this study.

Common side effects associated with the use of statins are elevated aminotransferase levels >3 times the upper limit of normal, (incidence of <1% in low-moderate statins dose and 2-3% in higher dose). These elevations are related to the dose of statins but not to the reduction of LDL-C. Severe liver injury is rare and the elevation of the aminotransferases is most often transient and will resolve spontaneously in 70% of cases even if the statins and doses are continued unchanged. The cause of elevation in liver transaminase levels is not well understood but proposed mechanisms, including a transient pharmacologic effect secondary to cholesterol reduction in hepatocytes, comorbid conditions such as diabetes mellitus and obesity, and the consumption of alcohol or non-statin medications. The most prevalent side effect with statin therapy is myalgia (1.5-3%). Serious muscle toxicity and rhabdomyolysis in 1.6 patients per 100,000 person-years and rhabdomyolysis in 1.6 patients per 100,000 person-years). The National Lipid Association Statin Safety Assessment Task Force does not recommend routine measurement of CK levels in asymptomatic patients during the course of statin therapy, because marked clinically important CK elevations are rare and are usually related to physical exertion or other causes.

In this study, there were no significant increases in liver enzymes and CK levels in patients treated with simvastatin.

**Conclusion**

Overall, this study showed that more than half of the high risk patients are not at target for LDL-C goals which place them at a continuous risk for CHD and their lipid lowering therapy using statins or combination therapy should be optimized to improve the chances of achieving LDL-C goals.

**Acknowledgements**

The authors reported no conflict of interest and no funding was received on this work.

**References**

12. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al; National Heart, Lung, and Blood Institute; American College


